Home > Journals > Minerva Cardiology and Angiology > Past Issues > Minerva Cardiology and Angiology 2022 June;70(3) > Minerva Cardiology and Angiology 2022 June;70(3):357-69

CURRENT ISSUE
 

JOURNAL TOOLS

Publishing options
eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

REVIEW  DIABETES AND HEART FAILURE 

Minerva Cardiology and Angiology 2022 June;70(3):357-69

DOI: 10.23736/S2724-5683.20.05454-7

Copyright © 2020 EDIZIONI MINERVA MEDICA

language: English

Diabetic cardiomyopathy and inflammation: development of hostile microenvironment resulting in cardiac damage

Edoardo ELIA 1, Stefano MINISTRINI 2, Federico CARBONE 2, 3, Fabrizio MONTECUCCO 2, 3,

1 Division of Cardiology, Department of Internal Medicine, Città della Salute e della Scienza, Turin, Italy; 2 First Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa, Genoa, Italy; 3 IRCCS Ospedale Policlinico San Martino, Genoa - Italian Cardiovascular Network, Genoa, Italy



Diabetes mellitus is emerging as a major risk factor for heart failure. Diabetic cardiomyopathy is defined as a myocardial dysfunction that is not caused by underlying hypertension or coronary artery disease. Studies about clinical features, natural history and outcomes of the disease are few and often conflicting, because a universally accepted operative definition of diabetic cardiomyopathy is still lacking. Hyperglycemia and related metabolic and endocrine disorders are the triggering factors of myocardial damage in diabetic cardiomyopathy through multiple mechanisms. Among these mechanisms, inflammation has a relevant role, similar to other chronic myocardial disease, such as hypertensive or ischemic heart disease. A balance between inflammatory damage and healing processes is fundamental for homeostasis of myocardial tissue, whereas diabetes mellitus produces an imbalance, promoting inflammation and delaying healing. Therefore, diabetes-related chronic inflammatory state can produce a progressive qualitative deterioration of myocardial tissue, which reflects on progressive left ventricular functional impairment, which can be either diastolic, with prevalent myocardial hypertrophy, or systolic, with prevalent myocardial fibrosis. The aim of this narrative review is to summarize the existing evidence about the role of inflammation in diabetic cardiomyopathy onset and development. Ultimately, potential pharmacological strategies targeting inflammatory response will be reviewed and discussed.


KEY WORDS: Diabetes mellitus; Myocardium; Heart failure; Immune system; Diabetic cardiomyopathies

top of page